Anti-SARS-CoV-2 Spike RBD (Clone: 2355) Purified No Carrier Protein
Produktgrößen
100 µg
£635,00
12-8433-100UG
500 µg
£873,00
12-8433-500UG
Über dieses Produkt
- SKU:
- 12-8433
- Zusätzliche Namen:
- COV2-2355; SARS-CoV-2 Spike RBD Antibody; Receptor Binding Domain Antibody
- Klonalität:
- Monoclonal
- Weitere Details:
- Specificity: Anti-SARS-CoV-2 Spike RBD; clone 2355; specifically targets an epitope on the SARS-CoV-2 spike protein receptor-binding domain (RBD). Antigen Distribution: The spike RBD is expressed on the surface of SARS-CoV-2. Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the causative agent of coronavirus disease 2019 (COVID-19); is an enveloped; single-stranded; positive-sense RNA virus that belongs to the Coronaviridae family 1. The SARS-CoV-2 genome; which shares 79.6% identity with SARS-CoV; encodes four essential structural proteins: the spike (S); envelope (E); membrane (M); and nucleocapsid protein (N) 2. The S protein is a transmembrane; homotrimeric; class I fusion glycoprotein that mediates viral attachment; fusion; and entry into host cells 3. Each ~180 kDa monomer contains two functional subunits; S1 (~700 a.a) and S2 (~600 a.a); that mediate viral attachment and membrane fusion; respectively. S1 contains two major domains; the N-terminal (NTD) and C-terminal domains (CTD). The CTD contains the receptor-binding domain (RBD); which binds to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells 3-5. Although both SARS-CoV and SARS-CoV-2 bind the ACE2 receptor; the RBDs only share ~73% amino acid identity; and the SARS-CoV-2 RBD binds with a higher affinity compared to SARS-CoV 3; 6. The RBD is dynamic and undergoes hinge-like conformational changes; referred to as the ?down? or ?up? conformations; which hide or expose the receptor-binding motifs; respectively 7. Following receptor binding; S1 destabilizes; and TMPRSS2 cleaves S2; which undergoes a pre- to post-fusion conformation transition; allowing for membrane fusion 8; 9. Polyclonal RBD-specific antibodies can block ACE2 binding 10; 11; and anti-RBD neutralizing antibodies are present in the sera of convalescent COVID19 patients 12; identifying the RBD as an attractive candidate for vaccines and therapeutics. In addition; the RBD is poorly conserved; making it a promising antigen for diagnostic tests 13 14. Serologic tests for the RBD are highly sensitive and specific for detecting SARS-CoV-2 antibodies in COVID19 patients 13 15. Furthermore; the levels of anti-RBD antibodies correlated with SARS-CoV-2 neutralizing antibodies; suggesting the RBD could be used to predict an individual's risk of disease 13.
- Isotyp:
- Human IgG1
- Aufreinigung:
- Purity :>=90% monomer by analytical SEC and SDS-PagePreparation : Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are pu
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- This antibody may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at
- Hersteller:
- Abeomics
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules
- Datenblatt des Herstellers:download_pdf.php